8-K: Xilio Therapeutics Announces Positive Phase 2 Data and First Quarter 2025 Financial Results

Xilio Therapeutics reports encouraging Phase 2 data for vilastobart in MSS CRC and advances multiple masked T cell engager programs, alongside Q1 2025 financial results.

Summary

• Xilio Therapeutics announced its Q1 2025 financial results and provided pipeline updates.
• The company presented encouraging initial Phase 2 data for vilastobart in combination with atezolizumab, showing a 27% objective response rate in late-line MSS CRC patients without liver metastases.
• Xilio is advancing multiple masked T cell engager programs, with first development candidates anticipated in the second half of 2025.
• A collaboration, license and option agreement with AbbVie was announced, providing Xilio with $52.0 million in upfront payments.
• Cash and cash equivalents totaled $89.1 million as of March 31, 2025.
• The company anticipates that its current cash will be sufficient to fund operations into the first quarter of 2026.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook due to encouraging clinical data, a significant collaboration agreement, and a strong cash position. However, ongoing losses and the need for future capital raise temper the overall sentiment.

Positives

• Encouraging Phase 2 data for vilastobart in MSS CRC patients without liver metastases.
• Collaboration with AbbVie provides significant upfront payments and potential future milestones.
• Advancement of multiple masked T cell engager programs.
• Strong cash position of $89.1 million as of March 31, 2025.
• Cash runway extends into the first quarter of 2026.

Negatives

• Research and development expenses remain high at $8.3 million for the quarter.
• General and administrative expenses increased to $8.5 million for the quarter.
• The company is still loss-making, with a net loss of $13.3 million for the quarter.

Risks

• The success of clinical trials is uncertain, and initial data may not be replicated in future trials.
• Regulatory approvals are not guaranteed and may be delayed.
• The company may need to raise additional capital beyond the first quarter of 2026.
• Reliance on collaboration agreements with AbbVie, Gilead, and Roche carries risks.
• The company faces risks related to intellectual property protection and enforcement.

Future Outlook

Xilio anticipates that its cash and cash equivalents as of March 31, 2025 will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the first quarter of 2026.

Management Comments

• Ren Russo, Pharm.D., president and chief executive officer of Xilio, stated that the initial Phase 2 data for vilastobart in combination with atezolizumab showed a preliminary 27% objective response rate in late-line MSS CRC patients without liver metastases and a differentiated safety profile.
• Ren Russo noted that MSS CRC is an immunologically cold tumor type that is very difficult to treat and increasing in incidence, particularly in younger people for whom no immunotherapy treatment options are currently available.

Industry Context

Xilio's focus on tumor-activated immuno-oncology therapies aligns with the industry trend of developing more targeted and safer cancer treatments. The collaboration with AbbVie and Gilead validates Xilio's technology and approach. The data presented at ASCO will be closely watched by competitors and potential partners.

Comparison to Industry Standards

• The 27% objective response rate for vilastobart in combination with atezolizumab in MSS CRC patients without liver metastases is a notable result in a difficult-to-treat cancer.
• Competitors like Bristol Myers Squibb (Opdivo) and Merck (Keytruda) have established immunotherapies, but Xilio's tumor-activated approach aims to improve safety and efficacy.
• The collaboration with AbbVie, with potential payments up to $2.1 billion, is comparable to other significant deals in the immuno-oncology space.
• The development of masked T cell engagers is in line with industry efforts to create more potent and selective immunotherapies.

Stakeholder Impact

• Shareholders will be encouraged by the positive clinical data and the AbbVie collaboration.
• Employees will benefit from the company's financial stability and growth prospects.
• Patients may have access to new and improved cancer treatments.
• The collaboration with AbbVie and Gilead strengthens Xilio's position in the immuno-oncology field.

Next Steps

• Report updated Phase 2 data for vilastobart at the ASCO Annual Meeting.
• Nominate development candidates for PSMA, CLDN18.2, and STEAP1 programs.
• Submit IND applications for XTX501, PSMA, CLDN18.2, and STEAP1 programs.
• Continue Phase 1A monotherapy dose escalation and Phase 1B monotherapy dose expansion of the ongoing Phase 1 clinical trial of XTX301.
• Seek opportunities to partner the vilastobart program to accelerate and expand further development.

Key Dates

Keywords

Xilio Therapeutics, vilastobart, XTX301, XTX501, immuno-oncology, T cell engager, MSS CRC, clinical trial, AbbVie, Gilead, ASCO, financial results